Astigmatism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Astigmatism Market Outlook
Thelansis’s “Astigmatism Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Astigmatism treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Astigmatism Overview
Astigmatism,
a prevalent refractive error, is characterized by alterations in the refraction
of light in different eye meridians. This condition results in the failure of
parallel rays of light passing through the cornea to converge on the retina at
a single focal point. Astigmatism can manifest as either regular or irregular.
Typical symptoms include asthenopia, discomfort, blurred and defective vision,
elongation of objects, and difficulties with accommodation. Signs of
astigmatism include partial lid closure, head tilt, vertically oval or tilted
optic disc, and varying power in different meridians. The underlying causes of
astigmatism can be attributed to corneal, lenticular, or retinal factors.
Regular astigmatism can further be classified into “with the rule” astigmatism,
“against the rule” astigmatism, oblique astigmatism, and bi-oblique
astigmatism. The principles of Sturm’s conoid elucidate the optics of regular
astigmatism. In regular astigmatism cases, parallel light rays converge into
two focal lines rather than focusing on a singular point. The arrangement of
rays refracted through the toric surface is known as Sturm’s conoid, and the
distance between these lines is referred to as the focal interval of Sturm.
Infants and neonates tend to exhibit higher degrees of astigmatism.
Approximately 40 percent of newborns have around 1 diopter of astigmatism at
birth, which typically diminishes to adult levels by one year due to normal eye
maturation and globe remodeling. Treatment for regular astigmatism typically
involves prescribing spectacles with cylindrical lenses that are determined
after accurate refraction. Another option for correcting astigmatism is using
rigid contact lenses, which can correct up to 2-3 diopters of astigmatism.
Toric contact lenses are recommended for astigmatism exceeding this range. The
prognosis for individuals with astigmatism is generally favorable if treated
promptly, as there are several options for correction. Failure to treat
astigmatism, particularly during childhood, can permanently reduce visual
acuity and the development of amblyopia. It is important to note that
astigmatism may change over time, necessitating new glasses and contact lenses.
Refractive correction often successfully eliminates or reduces astigmatism in most
cases. Individuals with keratoconus risk experiencing a decline in visual
acuity due to high astigmatism, underscoring the need for timely and regular
screenings.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment